Hualan Vaccine released the interim report for the first half of 2024. During the reporting period, the company achieved revenue of 35.5289 million yuan, a decrease of 76.25% year-on-year; the net income attributable to shareholders of the listed company was 25.2744 million yuan, a decrease of 76.65% year-on-year.
华兰疫苗：上半年净利润同比下降76.65%
Hualan Vaccine: The net income in the first half of the year decreased by 76.65% year-on-year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.